# Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

> **NCT02052141** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 12 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **BIOLOGICAL:** CINRYZE 500
- **BIOLOGICAL:** CINRYZE 1000

## Key facts

- **NCT ID:** NCT02052141
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-20
- **Primary completion:** 2017-05-04
- **Final completion:** 2017-05-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052141, "Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02052141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*